CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

Sex: All

Ages: 18 Years – 99 Years

Healthy volunteers: No

Phase: PHASE1

Enrollment: 30

Sponsor: University of Texas Southwestern Medical Center

Location: University of Chicago Comprehensive Cancer Center Chicago Illinois

Summary

This research study is being done to find out if the immunotherapy drugs called CDX-301 and CDX-1140 in combination with the standard chemotherapy treatment pegylated liposomal doxorubicin (PLD, Doxil) are safe and effective at controlling the cancer in patients with metastatic triple Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer, and to determine a safe dose and treatment schedule of the three drugs. This research study will also test how your immune system responds to these treatments alone and in combination.

Eligibility Criteria

Inclusion Criteria: * Unresectable Stage III or Stage IV HER2 negative breast cancer (either triple negative or hormone receptor positive) * Triple negative breast cancer for this study is defined as estrogen receptor \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05029999). StuddyBuddy aggregates publicly available trial information.